Besides EGFR T790M, other resistance mutations can only be detected by the UltraSEEKTM Lung Panel (in BRAF, ERBB2, KRAS and PIK3CA, as well as EGFR C797S) and could be are useful for treatment decision making for lung cancer patients. This evidence concerns the gene KRAS and lung carcinoma.